CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions

American Journal of Surgery

Volumn 198, Issue 3, 2009, Pages 333-339

  Marrelli, Daniele ^a   Caruso, Stefano ^a   Pedrazzani, Corrado ^a   Neri, Alessandro ^a   Fernandes, Eduardo ^b   Marini, Mario ^a   Pinto, Enrico ^a   Roviello, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

CA19 9; Endoscopic retrograde cholangiopancreatography; Obstructive jaundice; Pancreato biliary malignancy; Tumor marker

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; BILIARY TRACT DRAINAGE; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; COMMON BILE DUCT; COMMON BILE DUCT STONE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPY; FEMALE; GALLBLADDER CANCER; GALLBLADDER CARCINOMA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE JAUNDICE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VATER PAPILLA CARCINOMA; VATER PAPILLA STENOSIS;

ADULT; AGED; AGED, 80 AND OVER; BILIARY TRACT NEOPLASMS; CA-19-9 ANTIGEN; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DIAGNOSIS, DIFFERENTIAL; DRAINAGE; FEMALE; HUMANS; JAUNDICE, OBSTRUCTIVE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 69249222645     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2008.12.031     Document Type: Article

References (33)

1. Koprowski H., Steplewski Z., Mitchell K., et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Genet 5 (1979) 957-971
2. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 85 (1990) 350-355
3. Marrelli D., Roviello F., De Stefano A., et al. Prognostic significance of CEA, CA19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 57 (1999) 55-62
4. Marrelli D., Pinto E., De Stefano A., et al. Clinical utility of CEA, CA19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 181 (2001) 16-19
5. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95 (2000) 204-207
6. Ferrone C.R., Finkelstein D.M., Thayer S.P., et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 2897-2902
7. Halloran C.M., Ghaneh P., Connor S., et al. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 95 (2008) 453-459
8. Kim H.J., Kim M.H., Myung S.J., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 94 (1999) 1941-1946
9. Goonetilleke K.S., and Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33 (2007) 266-270
10. Ong S.L., Sachdeva A., Garcea G., et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Digest Dis Sci 53 (2008) 3213-3217
11. Paganuzzi M., Onetto M., Marroni P., et al. Ca 19-9 and Ca 50 in benign and malignant pancreatic and biliary diseases. Cancer 61 (1988) 2100-2108
12. Mann D.V., Edwards R., Ho S., et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000) 474-479
13. Cassidy L.D. Basic concepts of statistical analysis for surgical research. J Surg Res 128 (2005) 199-206
14. Haglund C., Roberts P.J., Kuusela P., et al. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53 (1986) 197-202
15. Albert M.B., Steinberg W.M., and Henry J.P. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Digest Dis Sci 33 (1988) 1223-1225
16. Yoshida E.M., Scudamore C.H., Erb S.R., et al. Markedly elevated serum CA 19-9 levels in a case of chronic pancreatitis. Can J Surg 38 (1995) 83-86
17. Maestranzi S., Przemioslo R., Mitchell H., et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 35 (1998) 99-103
18. Duffy M.J. 19-9 As a marker for gastrointestinal cancers: a review. Ann Clin Biochem 35 (1998) 364-370
19. Kodama T., Satoh H., Ishikawa H., et al. Serum levels of CA19-9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 21 (2007) 103-106
20. Ker C.G., Chen J.S., Lee K.T., et al. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol 6 (1991) 505-508
21. Basso D., Meggiato T., Fabris C., et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Eur J Clin Invest 22 (1992) 800-804
22. Dorizzi R.M., Di L.A., Guglielmi A., et al. Measurement of serum ca 19-9 in biliary diseases requires great caution. Acta Oncol 40 (2001) 877-878
23. Katsanos K.H., Kitsanou M., Christodoulou D.K., et al. Ca 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 13 (2002) 132-135
24. Sheen-Chen S.M., Sun C.K., Liu Y.W., et al. Extremely elevated CA19-9 in acute cholangitis. Digest Dis Sci 52 (2007) 3140-3142
25. Duraker N., Hot S., Polat Y., et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 95 (2007) 142-147
26. Kang C.M., Kim J.Y., Choi G.H., et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 140 (2007) 31-35
27. Vestergaard E.M., Hein H.O., Meyer H., et al. Reference values and biological variation for tumor marker ca 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 45 (1999) 54-61
28. Koroglu M., Koroglu B.K., Akhan O., et al. Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice. Hepatogastroenterology 53 (2006) 491-496
29. Barone D., Onetto M., Conio M., et al. CA 19-9 assay in patients with extrahepatic cholestatic jaundice. Int J Biol Markers 3 (1988) 95-100
30. Murray M.D., Burton F.R., and Di Bisceglie A.M. Markedly elevated serum CA19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J Clin Gastroenterol 41 (2007) 115-117
31. Madonia S., Aragona E., Maisano S., et al. Ca 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?. Digest Dis Sci 52 (2007) 1125-1127
32. Weston B.R., Ross W.A., Wolff R.A., et al. Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography?. Cancer 112 (2008) 2417-2423
33. Mortenson M.M., Katz M.H., Tamm E.P., et al. Current diagnosis and management of unusual pancreatic tumors. Am J Surg 196 (2008) 100-113